National Institute of Neurological Disorders and Stroke (NINDS)
New
None
93.853
The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. A staged approach will be used to first identify and address pre-analytical variables and then incorporate that information into the optimal design for the analysis of 4500 CSF and plasma samples.
April 5, 2019
April 29, 2019
May 29, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
Purpose
The purpose of the funding opportunity announcement (FOA) is to support the unbiased proteomic analysis of matched cerebrospinal fluid (CSF) and plasma samples collected by PD cohort studies represented in the Accelerating Medicine Partnership in Parkinson’s Disease (AMP PD). This FOA invites applications that will utilize an unbiased data independent acquisition (DIA) mass spectrometry (MS) platform to identify robust and reproducible CSF and plasma proteomes for age- and gender-matched Parkinson’s disease cases and healthy controls. Data (both raw and processed) generated by the DIA MS platform will be uploaded to the AMP PD cloud environment and workflows will be generated using Workflow Description Language (WDL) for deposition in the AMP PD methods repository. Jupyter notebooks will be developed to detail quality control analysis and to describe the overall processing of the proteomics data.
Background
The Accelerating Medicine Partnership in Parkinson’s disease (AMP PD), a component of the National Institute of Health (NIH) AMP program, was established in January 2018 as a public-private partnership managed by the Foundation for NIH (FNIH). The partnership includes representation from Celgene, the Food and Drug Administration (FDA), Glaxo Smith Kline (GSK), the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the National Institute for Neurological Disorders and Stroke (NINDS), Pfizer, Sanofi, and Verily. The mission of AMP PD is to identify and validate prognostic, progression and predictive biomarkers for Parkinson’s disease (PD). Projected outcomes of AMP PD include improvements in clinical trial design, better patient stratification, the ability to monitor disease progression and the potential to identify new pathways for therapeutic development.
AMP PD takes advantage of already existing PD cohorts including the MJFF Parkinson’s Progression Markers Initiative (PPMI), the MJFF/NINDS BioFIND cohort, the NINDS Parkinson’s Disease Biomarkers Program (PDBP) and the Harvard Biomarker Study (HBS). Clinical and genomic (whole genome sequencing and genotyping) data are available for 4,521 participants (2,812 PD cases, 1,709 healthy controls). Longitudinal clinical and transcriptomic data over 2 to 3 years are available for 697 PD cases and 312 healthy controls. Clinical data harmonization across the cohorts includes, demographics, family history of PD, PD medication, sub-scores and/or total scores for the Movement Disorder Society-Unified Parkinson’s disease Rating Scale (MDS-UPDRS), the Hoehn and Yahr scale, the Montreal Cognitive Assessment (MoCA), University of Pennsylvania Smell Identification Test (UPSIT), Epworth Sleepiness Scale, REM Sleep Behavioral Disorder Questions, the Parkinson’s Disease Questionnaire (PDQ39) and the modified Schwab and England ADL assessment.
Cerebrospinal fluid (CSF) was collected from PD patients and healthy control volunteers in a similar protocol across the various AMP PD cohorts, wherein the CSF was mixed prior to centrifugation at 2000g for 10 minutes at room temperature, followed by mixing and aliquoting into 1 ml polypropylene cryotubes and freezing at -80oC. CSF is usually distributed in 100 to 250 microliter aliquots and therefore will have gone through one freeze thaw cycle prior to DIA MS analysis. Hemoglobin is used as the CSF and plasma quality assessment measurement. Approximately 3100 longitudinal CSF samples are available for analysis. Plasma was collected in vacutainer EDTA tubes and centrifuged at 40C, 1500g for 15 minutes, prior to aliquoting into 1 ml polypropylene cryotubes. Plasma is usually distributed in 100 to 250 ml aliquots and therefore, like the CSF, will have gone through one freeze thaw cycle prior to DIA MS analysis. There are approximately 1400 CSF-matched baseline plasma samples available for analysis.
Pre-analytical variable assessment stage
The pre-analytical variable assessment stage will focus on the identification of pre-analytical variables that will impact the generation of robust and reproducible DIA MS results. Approximately 30 samples each of CSF and plasma, as well as pooled controls will be used for this analysis. The variables may include, but are not limited to:
The goal of the pre-analytical variance analysis is to maintain coefficients of variance among replicates and between runs at < or equal to 20%. Once sample and equipment handling conditions are standardized, the analysis will move into the scale-up stage.. It is anticipated that the pre-analytical analysis will take 2 to 4 months from receipt of biosamples.
MS Scale-up Stage
The MS scale-up stage will focus on the large scale DIA MS analysis of approximately 3100 CSF and 1400 plasma samples. During this phase, the study investigator(s) will work closely with the AMP PD proteomics working group and AMP PD data coordinator to develop quality assessment standards, data transfer protocols for storage in the AMP PD cloud environment and workflow and analysis pipelines for the proteomics data. The proteomic workflows will be generated using Workflow Description Language (WDL) for deposition in the AMP PD methods repository. Jupyter notebooks will be developed to detail quality control analysis and to describe the overall processing of the proteomics data. The initial analysis of MS data will focus on differential expression of proteins between PD cases and controls. All data generated will be broadly shared with the research community through the AMP PD Knowledge portal. To enable high throughput, high quality proteomics analysis, the sequencing facility(s) must be able to process 3100 longitudinal CSF and 1400 baseline plasma samples in an 8 to 10-month period. To meet this capacity demand, collaborations across several labs with common instrumentation and demonstration of similar quality standards may be necessary.
This FOA will not support:
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Need help determining whether you are doing a clinical trial?
The National Institute of Neurological Disorders and Stroke intends to commit up to $3,400,000 in FY19 to fund 1 award.
Application budgets need to reflect the actual needs of the proposed project.
1 year
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Governments
Applicant organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
Program Director(s)/Principal Investigator(s) must have demonstrated expertise in DIA MS analysis and experience in processing large numbers of CSF and plasma biosamples in an efficient, rigorous and reproducible manner.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Debra Babcock, PhD, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: dbabcock@mail.nih.gov
Facilities and Other Resources: In addition to standard items, applicants must describe the following:
The specialized or unique facilities, core resources, and services that each team member will provide towards achieving the objectives of the proposed studies.
The expert technical or advisory personnel and information of other components of the supporting infrastructure pertinent to the application.
Any relevant ongoing institutional, and/or private sector support and resources that augment or complement resources for which funding from this FOA is sought.
Available laboratory information management system, proteomics analysis tools, data storage, security, archiving, and retrieval systems. Applicants must also describe standardized formats for data reporting and the validation process for data prior to submission to the AMP PD Knowledge portal.
Program Director(s)/Principal Investigator(s) must have demonstrated expertise in DIA MS analysis and experience in processing large numbers of CSF and plasma biosamples in an efficient, rigorous and reproducible manner.
All instructions in the SF424 (R&R) Application Guide must be followed.
Research Strategy Overall
Demonstrate the depth of proteomes that can be studied using DIA MS with instrumentation available, including the dynamic range of the measurements that can be achieved in both CSF and plasma samples. Specifically, demonstrate what protein/peptide concentrations can be reproducibly achieved in the range of low femtomole/microgram to low femtomole/milligram (proteins). Preliminary data can be from any disease.
Demonstrate the ability to generate reproducible results within and across (if applicable) laboratories using standards and metrics in high-throughput, large-scale proteomic research studies.
Describe the capability to meet throughput requirements, including identifying maximal capability
Pre-analytical variable assessment (2-4 months)
Describe the pre-analytical variables to be assessed and the experiments to be performed to develop a standard operating procedure for biosample handling.
Describe a strategy to monitor and ensure the quality of instrument performance and data generated. Include plans to ensure implementation of metrics for instrument quality control and SOPs for sample storage/processing/analyses that enable less than or equal to 20% coefficient of variance across replicates and instrumentation runs. Examples of such metrics that provide evidence of adequate instrument performance may include (but are not limited to): reference materials, limits of detection, limits of quantitation, total number of unique protein identification and quantitation, and signal-to-noise ratio.
DIA MS Scale up (8-10 months)
Provide a workflow, with timeline for sample processing
Describe how data will be analyzed, including: descriptions of data processing, identification of algorithms and quantitation strategies, databases used, error rate analysis for protein/peptide identification, PTM site localization and quantitation.
The following modifications also apply:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed with the following additional instructions:
Do not use this form; applications proposing Human Subjects are non-responsive.Not applicable
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
Not applicable
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement .
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by the National Institute of Neurological Disorders and Stroke . Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Do the Director(s)/Principal Investigators(s) have demonstrated expertise in DIA MS analysis? Had the PD/PI successfully processed large numbers of CSF and plasma biosamples in an efficient, rigorous and reproducible manner?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project ? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Overall, does the preliminary data provided demonstrate adequate depth of proteomes generated including the dynamic range of measurements for the sample types to be studied? Does the preliminary data support the ability to obtain reproducible results within and across (if applicable) laboratories using standards and metrics in high-throughput, large scale proteomic research studies? Is the proteomic analysis capacity identified in the application sufficient to process the large number of AMP PD biosamples in an 8 to10 month time window? For preliminary data with plasma and CSF are the coefficients of variance less than or equal to 20% across replicates and instrumentation runs?
For the pre-analytical variable analysis, does the strategy for analysis of pre-analytical variables enable generation of robust and reproducible data that can be applied to a larger sample size?
For the MS scale-up staging, are a workflow and timeline provided for sample processing? Will the workflow enable processing of a large amount of proteomics data in a reasonable time period? Are the algorithms, and quantification strategies appropriate for the data to be processed? Is the error rate for analysis of protein/peptide identification, PTM site localization and quantification appropriate for the study, given a target error rate of 10-15%?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Do the specialized or unique facilities, core resources and or services provided meet the needs of the program? Does the institutional infrastructure such as expert technical or advisory personnel support the needs of the study? Is the laboratory information management system, proteomics analysis tools, data storage, security, archiving and retrieval appropriate and sufficient to support the study?
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Not Applicable.
Not Applicable.
Not Applicable.
Not Applicable.
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.
For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/index.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-individuals/section-1557/index.htmlhttps://www.hhs.gov/civil-rights/for-providers/laws-regulations-guidance/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see https://www.hhs.gov/civil-rights/for-individuals/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.
The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
Determining experimental approaches, designing protocols, setting project milestones and conducting experiments;
Awardees are expected to make new information and materials known to the research community not only in AMP PD face to face meetings but also in a timely manner through sharing of information through Google docs with the AMP PD proteomics working group, publications, web announcements, reports to NINDS program staff, and other mechanisms.
Publications
The PD(s)/PI(s) will be responsible for the timely submission of all abstracts, manuscripts and reviews (co)authored by project investigators and supported in whole or in part under this Cooperative Agreement. The PD(s)/PI(s) and Project Leaders are requested to submit manuscripts to the NIH Project Scientist within two weeks of acceptance for publication so that an up-to-date summary of program accomplishments can be maintained. Publications and oral presentations of work conducted under this Cooperative Agreement are the responsibility of the PD(s)/PI(s) and appropriate Project Leaders and will require appropriate acknowledgement of NINDS and AMP PD support. Timely publication of major findings is required.
NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
NINDS program staff will have substantial scientific/programmatic involvement during the conduct of this activity through technical assistance, advice and coordination. However, the role of NINDS Project Scientists will be to facilitate and not to direct the activities.
The NINDS Project Scientist will:
Areas of Joint Responsibility include:
None
Dispute Resolution:
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573
Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov
Debra Babcock, PhD, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: dbabcock@mail.nih.gov
Scientific Review Branch
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9223
Email: nindsreview.nih.gov@mail.nih.gov
Tijuanna Decoster, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9231
Email: decostert@ninds.nih.gov
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.